Teijin, Sigma-Tau ink orphan drug agreement in Japan
By Cornelia Zou
Wednesday, July 2, 2014
HONG KONG – A Japanese technology company has reached an agreement with a UK-based orphan drug developer to co-develop and sell an orphan drug in Japan.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.